<DOC>
	<DOCNO>NCT02322593</DOCNO>
	<brief_summary>The purpose trial evaluate efficacy TAS-118 plus Oxaliplatin compare S-1 plus Cisplatin overall survival patient advance gastric cancer .</brief_summary>
	<brief_title>Phase III Study TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Key Patients diagnose gastric cancer . No prior treatment gastric cancer . Negative unknown HER2 testing . ECOG performance status 0 1 . Key Unmanageable diarrhea . Current peripheral sensory neuropathy paresthesia . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Gastrointestinal Neoplasms</keyword>
	<keyword>First Line Treatment</keyword>
	<keyword>Antineoplastic Agents</keyword>
</DOC>